Goed nieuws voor het driemaandelijks toegediende STAR-0215
Early Trial Supporting 3-month Dosing With STAR-0215 for HAE
Patient trial possible next year into longer-acting preventative treatment
A single injection of STAR-0215, an experimental treatment to prevent swelling attacks in people with hereditary angioedema (HAE), safely led to rapid and sustained inhibition of the kallikrein protein in healthy adults, according to preliminary data from a Phase 1a trial.
“STAR-0215 has shown early proof of concept for its target profile: of being a long-acting preventative therapy for HAE … and dosing once every 3 months or less frequently,” said Jill C. Milne, PhD, CEO of Astria Therapeutics, the treatment’s developer, said in a company press release.
Kallikrein’s overactivity helps to drive the swelling attacks that mark HAE symptoms. STAR-0215, an antibody, aims to block this protein to prevent swelling episodes and to do so with the less frequent dosing requested by patients. Dosing intervals of up to six months are also being considered for testing.
Astria is planning to launch a proof-of-concept Phase 1b/2 global trial, to be called ALPHA-STAR, evaluating STAR-0215 in HAE patients early next year.